Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences

Zynerba Pharmaceuticals

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting, being held virtually October 18-30, 2021.

Presentation Details

Society for Developmental & Behavioral Pediatrics (SDBP) Annual Meeting

Title A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
Presentation Type Oral
Session Platform 2: NDD Phenotypes and Treatment
Date Saturday, October 23, 2021
Time 4:00 – 5:30 p.m. ET
Title Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])
Presentation Type Poster
Session Poster Session 2: Neurodevelopmental Disabilities, COVID-19
Date Monday, October 25, 2021
Time 1:45 – 2:45 p.m.
READ:  Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
68th American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting
Title RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX (ZYN2-CL-016)
Presentation Type Oral
Session Research Pipeline: New Findings on Diagnostic and Therapeutics
Date Wednesday, October 27, 2021
Time 3:15 p.m. – 5:30 p.m. ET
Title Longer-Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])
Presentation Type Oral
Session Research Pipeline: New Findings on Diagnostic and Therapeutics
Date Wednesday, October 27, 2021
Time 3:15 p.m. – 5:30 p.m. ET
Copies of the presentations and posters will be available on the Zynerba corporate website following each presentation at http://zynerba.com/publications/.

READ:  Virpax Pharmaceuticals Reports 2021 Third Quarter Results, Recent Developments

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.